Clinical Trials Browser

Phase 1/2 × Immunoconjugates × 90 days × Clear all

NCT06014658 2026-03-02

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

Phase 1/2 Recruiting

Neoplasms